Who should not take VIP (Vasoactive Intestinal Peptide)?
Documented caution flags for VIP (Vasoactive Intestinal Peptide) include hypotension or unstable cardiovascular status and pregnancy / nursing. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for VIP (Vasoactive Intestinal Peptide) is limited.
Documented caution flags for VIP (Vasoactive Intestinal Peptide)
- Hypotension or unstable cardiovascular status
- Pregnancy / nursing
- CIRS protocol specifically requires baseline biotoxin clearance first
Reported side effects to weigh
- Mild flushing
- Injection-site reaction (if sub-q)
- Rare: hypotension at high doses
References
- Vasoactive intestinal peptide (VIP) and inflammation, review — Delgado M & Ganea D, Amino Acids, 2013
- Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells — Sun X et al., World Journal of Gastroenterology, 2020
- Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis — Eger M et al., Frontiers in Pharmacology, 2021
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on VIP (Vasoactive Intestinal Peptide)
Full VIP (Vasoactive Intestinal Peptide) breakdownVIP (Vasoactive Intestinal Peptide) what it's used forVIP (Vasoactive Intestinal Peptide) side effectsVIP (Vasoactive Intestinal Peptide) how to take itVIP (Vasoactive Intestinal Peptide) mistakes to avoidVIP (Vasoactive Intestinal Peptide) half-lifeVIP (Vasoactive Intestinal Peptide) how long to workVIP (Vasoactive Intestinal Peptide) legal statusVIP (Vasoactive Intestinal Peptide) how it worksAsk the AI Coach
Last updated 2026-06-15.